FREE Account Opening + No Clearing Fees

Nirman Agri NSE SME IPO review (May apply)

Review By Dilip Davda on March 10, 2023

•    NAGL is in the business of producing, processing and marketing hybrid seeds, pesticides, and bio-organic for a variety of products.
•    It has posted growth in its top and bottom lines for the reported periods. 
•    The IPO appears fully priced based on its super earnings for FY23 so far. 
•    Well-informed investors may consider investing with a long-term perspective.
Nirman Agri Genetics Ltd. (NAGL) is one of the organized Agri-Input Companies in India engaged in the business of production, processing and marketing of high-quality hybrid seeds, Pesticides, and Bio-organic for different crops like corn, sunflower, cotton, paddy, grain sorghum, etc. and has recently forayed into micronutrients and bioproducts. It also produces non-hybrid seeds, primarily for paddy. 

NAGL currently has production, outsourced processing and R&D facilities in Maharashtra at Nashik and Nimgul and in Gujarat as well as Madhya Pradesh. NAGL's research mainly focuses on developing superior hybrids in different crops like corn, cotton, sunflower, paddy, bajra, etc. All the seed varieties developed by the R&D team are marketed under the brand name 'Nirman Agri Genetics'. 

In the year 2022, it began to market bio-pesticides, bio-fertilizers, micronutrients, fertilizer mixtures & plant growth regulators under the name and style of "Nirman Agri Genetics". Seeds, bio-fertilizers, micronutrients etc. are related products having the same end user i.e. the farmer and are usually sold through similar dealer networks. With a view of achieving the benefit of synergy in marketing the aforesaid products, it has recently added them to its product portfolio. 

It has a marketing network with loyal and committed distributors/dealers in Maharashtra Madhya Pradesh & Gujarat. Its focus is to become a leading crop solutions provider to the farmer by supplying high-yielding hybrid seeds and crop management through micronutrients, bioproducts etc. As of December 31, 2022, it had 40 employees on its payroll. 

The company is coming out with a maiden IPO of 2050800 equity shares of Rs. 10 each at a fixed price of Rs. 99 per share to mobilize Rs. 20.30 cr. The issue opens for subscription on March 15, 2023, and will close on March 20, 2023. The minimum application is to be made for 1200 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on NSE SME Emerge. The issue constitutes 34.40% of the post-IPO paid-up capital of the company. NAGL is spending Rs. 2.30 cr. for the IPO process indicating of arranged funding, and from the net proceeds, it will utilize Rs. 11.82 cr. for working capital, and Rs. 2.00 cr. for investment in strategic acquisition/JV, Rs. 0.45 cr. for purchase of computers/hardware, and Rs. 3.73 cr. for general corporate purposes.  

First Overseas Capital Ltd. is the sole lead manager and Bigshare Services Pvt. Ltd. is the registrar of the issue. NNM Securities Pvt. Ltd. is the market maker for the company. 

The company has issued/converted entire equity shares at par so far and has also issued bonus shares in the ratio of 255 for 1 in October 2022. The average cost of acquisition of shares by the promoters is Rs. 3.72 per share.  

Post-IPO, NAGL's current paid-up equity capital of Rs. 3.91 cr. will stand enhanced to Rs. 5.96 cr. Based on the IPO pricing, the company is looking for a market cap of Rs. 59.01 cr. 

On the financial performance front, for the last three fiscals, NAGL has (as per the proforma consolidated statement on a restated basis) posted a turnover/net profit of Rs. 2.59 cr. / Rs. 0.13 cr. (FY20), Rs. 7.78 cr. / Rs. 0.19 cr. (FY21), and Rs. 18.39 cr. / Rs. 2.73 cr. (FY22). For the first seven months of FY23 ended on October 31, 2022, it earned a net profit of Rs. 2.30 cr. on a turnover of Rs. 18.04 cr. According to the management, from this fiscal, it started bio-organic products marketing with three state Governments of Maharashtra, MP and Gujarat. This has lifted their top and bottom lines. They are putting major thrusts on these activities post-IPO to reap the benefits of good responses received. 

As per the restated financial performance, the company posted a turnover/net profit of Rs. 3.82 cr. / Rs. 0.05 cr. (FY21), Rs. 13.49 cr. / Rs. 2.56 cr. (FY22). For the period ended on October 31, 2022, of FY23, it earned a net profit of Rs. 2.30 cr. on a turnover of Rs. 18.04 cr. 

For the last three fiscals (till October 31, 2022), NAGL has reported an average EPS of Rs. 7.87 and an average RoNW of 72.11%. The issue is priced at a P/BV of 5.66 based on its NAV of Rs. 17.48 as of October 31, 2022, and at a P/BV of 2.23 based on its post-IPO NAV of Rs. 44.35 per share. 

If we annualize FY23 earnings and attribute them to post-IPO fully diluted paid-up equity capital, the asking price is at a P/E of 14.93. Thus the issue appears fully priced on the basis of super earnings of FY23 so far. 

The company has not declared any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy post-listing, based on its financial performance and future prospects. 

As per the offer document, the company has shown Upsurge Seeds, Bombay Super Seeds, and Shreeoswal Seeds as their listed peers. They are currently trading at a P/E of 58.20, 148.23, and 126.87 (as of March 10, 2023.) However, they are not truly comparable on an apple-to-apple basis. 

This is the 23rd mandate from First Overseas in the last five fiscals (including the ongoing one). Out of the last 10 listings, 2 opened at par and the rest were listed at premiums ranging from 2.50% to 43.53% on the listing date. 

Conclusion / Investment Strategy

NAGL is in the business of hybrid seeds manufacturing and marketing along with related bio-organic products. Based on its FY23 super earnings, the issue appears fully priced. Dilution of over 34% equity raise concern. Well-informed investors may consider an investment with a long-term perspective.

Review By Dilip Davda on March 10, 2023

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Nirman Agri Genetics IPO FAQs

  1. 1. Why Nirman Agri Genetics IPO?

    The initial public offer (IPO) of Nirman Agri Genetics Limited offers an early investment opportunity in Nirman Agri Genetics Limited. A stock market investor can buy Nirman Agri Genetics IPO shares by applying in IPO before Nirman Agri Genetics Limited shares get listed at the stock exchanges. An investor could invest in Nirman Agri Genetics IPO for short term listing gain or a long term.

  2. 2. How is Nirman Agri Genetics IPO?

    Read the Nirman Agri Genetics IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Nirman Agri Genetics IPO what should investors do?

    Nirman Agri Genetics IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Nirman Agri Genetics IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Nirman Agri Genetics IPO good?

    Our recommendation for Nirman Agri Genetics IPO is to subscribe for long term.

  5. 5. Is Nirman Agri Genetics IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe for long term to the Nirman Agri Genetics IPO.

  6. 6. When will Nirman Agri Genetics IPO allotment status?

    The Nirman Agri Genetics IPO allotment status will be available on or around March 23, 2023. The allotted shares will be credited in demat account by March 27, 2023. Visit Nirman Agri Genetics IPO allotment status to check.

  7. 7. When will Nirman Agri Genetics IPO list?

    The Nirman Agri Genetics IPO will list on Tuesday, March 28, 2023, at NSE SME.